Atlas Venture Fund Xi, L.P. Dyne Therapeutics, Inc. (DYN) insider trading activity

Atlas Venture Fund Xi, L.P. is of Dyne Therapeutics, Inc.. Currently has a direct ownership of 5.7 Million shares of DYN, which is worth approximately $166 Million. The most recent transaction as insider was on Feb 28, 2024, when has been sold 154,674 shares (Common Stock) at a price of $25.04 per share, resulting in proceeds of $3,873,036. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 5.7M

0% 3M change

22.22% 12M change

Total Value Held $166 Million

Atlas Venture Fund XI, L.P. Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 28 2024	SELL Open market or private sale	$3,873,036 $25.04 p/Share	154,674 Reduced 2.64%	5,698,091 Common Stock
Feb 27 2024	SELL Open market or private sale	$7,327,160 $24.53 p/Share	298,702 Reduced 4.86%	5,852,765 Common Stock
Feb 26 2024	SELL Open market or private sale	$4,784,050 $23.79 p/Share	201,095 Reduced 3.17%	6,151,467 Common Stock
Feb 23 2024	SELL Open market or private sale	$3,621,603 $22.7 p/Share	159,542 Reduced 2.45%	6,352,562 Common Stock
Feb 22 2024	SELL Open market or private sale	$2,704,697 $22.66 p/Share	119,360 Reduced 1.8%	6,512,104 Common Stock
Feb 21 2024	SELL Open market or private sale	$4,204,777 $22.79 p/Share	184,501 Reduced 2.71%	6,631,464 Common Stock
Feb 20 2024	SELL Open market or private sale	$3,907,873 $23.05 p/Share	169,539 Reduced 2.43%	6,815,965 Common Stock
Feb 16 2024	SELL Open market or private sale	$3,765,039 $23.14 p/Share	162,707 Reduced 2.28%	6,985,504 Common Stock
Feb 15 2024	SELL Open market or private sale	$4,299,988 $24.17 p/Share	177,906 Reduced 2.43%	7,148,211 Common Stock
Jul 13 2021	SELL Other acquisition or disposition	-	814,013 Reduced 10.0%	7,326,117 Common Stock

Also insider at

DAWN

Day One Biopharmaceuticals, Inc. Healthcare

> 10% Shareholder

XLO

Xilio Therapeutics, Inc. Healthcare

> 10% Shareholder

IKNA

Ikena Oncology, Inc. Healthcare

> 10% Shareholder

THRD

Third Harmonic Bio, Inc. Healthcare

> 10% Shareholder

AVF